This interactive web-app was designed to illustrate the features of the ProBio study using simulated examples under different scenarios:
scenario 1: no treatment works better in any signature
scenario 2: one treatment (Carboplatin) works better (HR = 0.5)
scenario 3: one treatment (Carboplatin) works better (HR = 0.4) only in the disease subtype belonging to the signature DRD+
scenario 4: hormonal therapies work better in the signature TP53- & AR-, Carboplatin in the signature DRD+, while chemotherapies work better in the signature TEfus+ with HR ranging from 0.4 to 0.27.
Read the pdf in the panel Stat to know more on how probabilities of superiority are computed.
Additional slides are available here for describing the aim, study design and main statistical aspects of the ProBio study.
Scenario 1
Treatment effects accross disease subtypes in terms of progression free survival (PFS)